-
-
EU Confirms Vision Risk Tied to Semaglutide
EMA
EU regulators have confirmed a rare risk of vision loss linked to Novo Nordisk’s semaglutide, used in Wegovy and Ozempic. Drug labels will be updated to reflect the potential for NAION, a serious but very rare eye condition.
-
-
-
EMA Takes Action on Metamizole-Induced Risks
EMA
The EMA has issued new recommendations to mitigate agranulocytosis risks associated with metamizole, urging increased awareness among healthcare providers and patients. Symptoms include fever and sore throat; immediate medical attention is crucial.
-
-
-
EMA's CHMP June 2024 Approvals and Recommendations
EMA
In June 2024, the EMA's CHMP recommended 10 new medicines for approval, including Balversa for urothelial carcinoma and Eurneffy, the first nasal spray for allergic reactions. Notable approvals also include mResvia, an mRNA vaccine for RSV, and treatments for various cancers and rare diseases.
-
-
凤翔县|
辽宁省|
会理县|
蓬安县|
南康市|
五峰|
阳东县|
永安市|
称多县|
武平县|
聂拉木县|
凤山县|
巴林右旗|
云阳县|
阜宁县|
石门县|
甘谷县|
普兰店市|
那坡县|
广河县|
陵川县|
鲁山县|
九龙县|
黄大仙区|
北票市|
吉安县|
新兴县|
林芝县|
称多县|
新晃|
香河县|
张家港市|
微山县|
潢川县|
潮安县|
丰都县|
双桥区|
隆昌县|
宁南县|
贵港市|
驻马店市|